In a 54-year-old male with a reduced ejection fraction (25%) after cardiac catheterization and type 2 diabetes with an elevated hemoglobin A1c (7.8%) who is only on metformin, should I start an SGLT2 inhibitor?

Yes, Start an SGLT2 Inhibitor Immediately

You should absolutely start an SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) in this patient now. This patient has two compelling indications: heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes with established cardiovascular disease (post-cardiac catheterization implies coronary disease evaluation).

Why SGLT2 Inhibitors Are Essential Here

Heart Failure Indication (Primary Driver)

With an ejection fraction of 25%, this patient has severe HFrEF. SGLT2 inhibitors are Class I, Strong Recommendation therapy for all patients with HFrEF, regardless of diabetes status 1, 2. The evidence is unequivocal:

• DAPA-HF and EMPEROR-Reduced trials showed ~25% reduction in the composite of cardiovascular death or heart failure hospitalization 1, 2
• 30% reduction in heart failure hospitalizations specifically 1
• 17-18% reduction in all-cause mortality 1
• Benefits occur independent of diabetes status 1, 3, 1

The 2022 ACC/AHA/HFSA guidelines and 2021 Canadian guidelines both give SGLT2 inhibitors the highest level of recommendation for HFrEF 1, 2. This is not optional therapy—it's foundational, on par with ACE inhibitors/ARNIs, beta-blockers, and mineralocorticoid receptor antagonists.

Diabetes with Cardiovascular Disease (Secondary Indication)

This patient also has type 2 diabetes (A1c 7.8%) with established cardiovascular disease. Guidelines strongly recommend SGLT2 inhibitors for patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce heart failure hospitalization and death 4, 1. The cardiovascular outcome trials (EMPA-REG OUTCOME, CANVAS) showed 31% reduction in heart failure hospitalizations in diabetic patients with or at high risk for cardiovascular disease 4, 2.

Specific Drug Selection

Choose either:

• Dapagliflozin 10 mg once daily (preferred based on DAPA-HF data) 1, 3, 1
• Empagliflozin 10 mg once daily (can increase to 25 mg if needed) 1, 3, 1

Both have equivalent Class I evidence for HFrEF. Dapagliflozin has slightly more robust mortality data (17% reduction in all-cause mortality, p=0.004) 1, while empagliflozin showed consistent cardiovascular death reduction in meta-analyses 2.

Addressing the Metformin Question

Continue metformin unless contraindicated by renal function. The patient needs his eGFR checked:

• If eGFR ≥45 mL/min/1.73 m²: Continue metformin at current dose 5, 6
• If eGFR 30-44 mL/min/1.73 m²: Reduce metformin to maximum 1000 mg/day 5, 6
• If eGFR <30 mL/min/1.73 m²: Discontinue metformin 5, 6

The SGLT2 inhibitor is MORE important than metformin in this clinical context because of the heart failure indication 1, 7, 1. If you had to choose one drug, choose the SGLT2 inhibitor.

Practical Implementation

Before Starting:

• Check eGFR: SGLT2 inhibitors can be initiated if eGFR ≥20 mL/min/1.73 m² 5, 1
  • DAPA-HF excluded eGFR <30, but EMPEROR-Reduced allowed ≥20 1
  • Current consensus supports initiation at eGFR ≥20 5
• Check blood pressure: Ensure systolic BP >95-100 mm Hg 1
• Review volume status: Patient should be euvolemic, not acutely decompensated 1, 8

Medication Adjustments:

• If A1c <8.5%: Reduce insulin by 20% and stop sulfonylureas to prevent hypoglycemia 8
• If on loop diuretics: No routine adjustment needed, but monitor volume status 1
• No need to wait for "optimal" doses of other heart failure medications—SGLT2 inhibitor benefits are additive regardless of background therapy 8

Monitoring:

• Week 1-2: Assess for genital mycotic infections (6% risk, higher in women) 5, 1
• Month 1: Recheck eGFR (expect 5-15% reversible decline), electrolytes, blood glucose 1
• Ongoing: Continue SGLT2 inhibitor even if eGFR falls below initiation threshold, unless dialysis is started 5

Critical Safety Points

Low Risk of Adverse Events:

• Hypoglycemia: Rare without insulin/sulfonylureas 1, 8
• Diabetic ketoacidosis: <0.3% risk, lower than placebo in heart failure trials 8
• Hypotension: Minimal effect on blood pressure 8
• Acute kidney injury: No excess risk; actually protective 5, 8

Sick Day Management:

Temporarily hold SGLT2 inhibitor during:

• Acute illness with reduced oral intake 1, 7
• Planned surgery (stop 3 days before) 4
• Volume depletion/dehydration 7

Contraindications:

• Type 1 diabetes 1
• eGFR <20 mL/min/1.73 m² (relative) 1
• Active dialysis 4
• History of serious hypersensitivity 4

Why Not Wait?

Every month of delay increases risk. Patients with HFrEF have:

• 25% risk of death or heart failure hospitalization within 18 months without SGLT2 inhibitors 1, 2
• Residual risk remains high even on other guideline-directed medical therapy 1, 8

The DAPA-HF and EMPEROR-Reduced trials showed benefit within months of initiation 1, 2. Starting early in the disease course is reasonable and recommended 1.

The Bottom Line Algorithm

1. Check eGFR and blood pressure today
2. If eGFR ≥20 and systolic BP >95 mm Hg → Start dapagliflozin 10 mg or empagliflozin 10 mg immediately
3. Adjust metformin based on eGFR (reduce if 30-44, stop if <30)
4. Reduce insulin 20% and stop sulfonylureas if A1c <8.5%
5. Counsel on genital hygiene and sick day rules
6. Recheck labs in 1 month
7. Continue SGLT2 inhibitor indefinitely unless dialysis or intolerance

This is not a "consider" situation—this is a "must do" for mortality and morbidity reduction 1, 2.